公开(公告)号：WO2020178738A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051807

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/12 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020154137A1

公开(公告)日：2020-07-30

申请号：PCT/US2020/013585

申请日：2020-01-15

Applicant: GENERAL ELECTRIC COMPANY ,  UNIVERSITY HEALTH NETWORK

Inventor： MADHAVAN, Radhika ,  BOUTET, Alexandre ,  JOEL, Suresh ,  HANCU, Ileana ,  ASHE, Jeffrey ,  LOZANO, Andres M.

IPC: A61N1/36 ,  A61B6/00 ,  G16H50/00 ,  G16H70/00 ,  A61B5/055

Abstract: A system for optimizing parameters of a DBS pulse signal for treatment of a patient is provided. In predicting optimal DBS parameters, functional brain data is input into a predictor system (1), the functional brain data acquired responsive to a sweeping across a multi-dimensional parameter space of one or more DBS parameters. Statistical metrics of brain response are extracted from the functional brain data for one or more ROIs or voxels of the brain via the predictor system (1), and a DBS functional atlas is accessed, via the predictor system (1), that comprises disease-specific brain response maps derived from DBS treatment at optimal DBS parameter settings for a plurality of diseases or neurological conditions. One or more optimal DBS parameters are predicted for the patient based on the statistical metrics of brain response and the DBS functional atlas via the predictor system (1).

公开(公告)号：WO2020124248A1

公开(公告)日：2020-06-25

申请号：PCT/CA2019/051866

申请日：2019-12-19

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： ZHANG, Li ,  LEE, Jong Bok ,  KANG, Hyeonjeong

IPC: C12N5/0783 ,  A01N1/02 ,  A61K35/17 ,  A61P35/00

Abstract: Described are methods for the production and use of cryopreservable double negative T cells (DNTs) for the treatment of cancer as an off-the-shelf cellular therapy. A sample population of DNTs is expanded using DNTs from one or more donors. The expanded population of DNTs from different donors does not exhibit alloreactivity against allogenic cells in the expanded population. The expanded populations of DNTs can be long-term stored as cryopreserved products.

公开(公告)号：WO2020118452A1

公开(公告)日：2020-06-18

申请号：PCT/CA2019/051813

申请日：2019-12-13

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KESHAVJEE, Shafique ,  LIU, Mingyao ,  CYPEL, Marcelo ,  SAGE, Andrew

IPC: G01N33/48 ,  G01N33/53 ,  G01N33/543 ,  G06F16/90 ,  G06N20/00

Abstract: Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of at least three biomarkers selected from IL-6, IL-8, IL-10 and IL-1β optionally in combination with one or both of sTNFR1 and sTREM1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of the at least three biomarkers selected from IL-8, IL-6, IL-10 and IL-1β and optionally one or both of sTNFR1 and sTREM1 i; and iii. a) comparing the one or more parameter values related to a level of the at least three biomarkers in the perfusate sample with control EVLP data or a cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the one or more parameter values related to a level of the at least three biomarkers in combination, as part of an algebraic calculation or model of outcome/risk.

公开(公告)号：WO2020058882A1

公开(公告)日：2020-03-26

申请号：PCT/IB2019/057882

申请日：2019-09-18

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KELLER, Gordon ,  GAGE, Blair Kenneth

IPC: C12N5/071 ,  A61K35/44 ,  A61P1/16 ,  C12N5/073 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/48 ,  G01N33/53

Abstract: Disclosed herein are methods of producing a population of venous angioblast cells from stem cells using a venous angioblast inducing media and optionally isolating a CD34+ population from the cell population comprising the venous angioblast cells, for example using a CD34 affinity reagent, CD31 affinity reagent and/or CD144 affinity reagent, optionally with or without a CD73 affinity reagent as well as methods of further differentiating the venous angioblasts in vitro to produce SEC-LCs and/or in vivo to produce SECs. Uses of the cells and compositions comprising the cells are also described.

公开(公告)号：WO2019241880A1

公开(公告)日：2019-12-26

申请号：PCT/CA2019/050853

申请日：2019-06-17

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： KHOSRAVI, Niloufar ,  MAEDA, Azusa ,  DA COSTA, Ralph S. ,  DAVIES, John E.

IPC: A61L15/42 ,  A61L27/56

Abstract: Compositions, products and devices are provided for promoting wound healing. The compositions, products and devices have a topographical complex surface.

公开(公告)号：WO2019148268A1

公开(公告)日：2019-08-08

申请号：PCT/CA2019/000015

申请日：2019-02-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： DACOSTA, Ralph ,  GIBSON, Christopher ,  OTTOLINO-PERRY, Kathryn ,  ANANTHA, Nayana, Thalanki ,  DONE, Susan, Jane ,  LEONG, Wey-Liang ,  EASSON, Alexandra M.

IPC: A61B5/00 ,  A61K49/00 ,  G06T7/90 ,  G16H50/20

Abstract: A method of assessing surgical margins is disclosed. The method includes, subsequent to administration of a compound configured to induce emissions of between about 600 nm and about 660 nm in cancerous tissue cells, positioning a distal end of a handheld, white light and fluorescence-based imaging device adjacent to a surgical margin. The method also includes, with the handheld device, substantially simultaneously exciting and detecting autofluorescence emissions of tissue cells and fluorescence emissions of the induced wavelength in tissue cells of the surgical margin. And, based on a presence or an amount of fluorescence emissions of the induced wavelength detected in the tissue cells of the surgical margin, determining whether the surgical margin is substantially free of at least one of precancerous cells, cancerous cells, and satellite lesions. The compound may be a non-activated, non-targeted compound such as ALA.

公开(公告)号：WO2019136558A1

公开(公告)日：2019-07-18

申请号：PCT/CA2019/050031

申请日：2019-01-09

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： WEAVER, Donald ,  BRANT, Michael G. ,  WOHNIG, Stephanie ,  WU, Fan ,  GOODWIN-TINDALL, Jake ,  MEEK, Autumn ,  SCHIAVINI, Paolo

IPC: C07D403/04 ,  A61K31/4178 ,  A61K31/454 ,  A61P25/28 ,  A61P3/00 ,  A61P35/00 ,  C07D401/14

Abstract: Inhibition of indoleamine 2,3-dioxygenase (IDOl) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of Formula (la) and (lb) of IDO, their synthesis, and uses thereof are provided.

公开(公告)号：WO2019084659A1

公开(公告)日：2019-05-09

申请号：PCT/CA2018/000203

申请日：2018-11-01

Applicant: UNIVERSITY HEALTH NETWORK ,  SINAI HEALTH SYSTEM

Inventor： DE CARVALHO, Daniel, Diniz ,  BRATMAN, Scott, Victor ,  CHAKRAVARTHY, Ankur, Ravinarayana ,  SINGHANIA, Rajat ,  BURGENER, Justin, Matthew ,  SHEN, Shu Yi

IPC: C12Q1/6809 ,  C12M1/34 ,  C12Q1/6806 ,  C12Q1/6869 ,  G01N1/40 ,  G16B30/00

Abstract: There is described herein a method of detecting the presence of DNA from cancer cells in a subject comprising: providing a sample of cell-free DNA from a subject; subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; optionally denaturing the sample; capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; sequencing the captured cell-free methylated DNA; comparing the sequences of the captured cell- free methylated DNA to control cell-free methylated DNAs sequences from healthy and cancerous individuals; identifying the presence of DNA from cancer cells if there is a statistically significant similarity between one or more sequences of the captured cell- free methylated DNA and cell-free methylated DNAs sequences from cancerous individuals.

公开(公告)号：WO2018191810A1

公开(公告)日：2018-10-25

申请号：PCT/CA2018/000068

申请日：2018-04-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BADIWALA, Mitesh, Vallabh ,  RAO, Vivek ,  ZU, Jean, W. ,  GELLNER, Bryan ,  RIBEIRO, Roberto, Vanin, Pinto ,  XIN, Liming

IPC: A01N1/02

Abstract: Systems and methods for performing perfusion and contractility assessments for a heart are provided. The system can operate in any of Langendorff mode, pump-supported working mode, passive working mode, and right-sided working mode. The system includes a reservoir from which one or more pumps are operable to supply a heart with fluids and collect fluids output therefrom. One or more clamps can be used to switch between Langendorff, pump-supported, passive, and right-sided working modes.